Clinical Services
The GSC is CAP and DAP certified to provide whole genome sequencing up to the production of BAM files.
Our Oncopanel detects mutations with known occurrence in the development of solid tumours within the following 48 genes:
AKT1, ALK, APC, ATM, BMPR1A, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, CHEK2, CIC, EGFR, ERBB2 (HER2), ERBB3 (HER3), FUBP1, GNAQ, GNA11, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (MEK1), MET (HGFR), MLH1, MSH2, MSH6, MUTYH, NF1, NRAS, PALB2, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PTEN, RET, ROS1, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53.
The current turnaround time is 12-17 days from receipt of the sample to mailing of the report.
If ordering within British Columbia, please refer to the Cancer Genetics Lab website.
If ordering from outside of British Columbia, please contact us for details and requisition forms.
The development of our next-generation sequencing assay is described in Bosdet et al. 2013.
Our Myeloid Panel detects mutations associated with acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes, in the following 52 genes:
ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DKC1, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KDM6A, KIT, KMT2A(MLL), KRAS, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PRPF40B, PTEN, PTPN11, RAD21, RTEL1, RUNX1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SOCS3, SRSF2, STAG2, TERC, TERT, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2.
The current turnaround time is 12-17 days from receipt of the sample to mailing of the report.
If ordering within British Columbia, please refer to the Cancer Genetics Lab website.
If ordering from outside of British Columbia, please contact us for details and requisition forms.
The development of our next-generation sequencing assay is described in Bosdet et al. 2013.
Our Hereditary Cancer Panel is available to people across Canada and includes testing for mutations in the following 19 genes:
APC, ATM, BMPR1A, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
This panel replaced BRCA1/2 testing in British Columbia in October 2014.
Current turnaround time is 8 weeks.
A list of ACMG 1, 2 and 3 variants with clinical interpretation will be reported.
Variants in exons 12 and 15 of PMS2 are not reported.
MLPA for copy number changes is offered for BRCA1, BRCA2, MLH1 and MSH2 upon request.
Referrals for this assay must be requested through BC Cancer's Hereditary Cancer Program.
If ordering from outside of British Columbia, please contact us for details and requisition forms.